Benzinga | Nov 9, 2021 11:45AM EST

Jasper Therapeutics Announces Research Collaboration With AVROBIO To Evaluate JSP191 As Conditioning Agent In Clinical Studies Of Ex Vivo Lentiviral Gene Therapy

Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biotechnology company focused on hematopoietic stem cell therapeutics, today announced that it has entered into a non-exclusive research collaboration with AVROBIO, Inc. to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1 who are being treated with one of AVROBIO's investigational ex vivo lentiviral gene therapies.

"This collaboration with AVROBIO further expands the potential of JSP191 for use with lentiviral gene therapies," said Bill Lis, executive chairman and chief executive officer of Jasper Therapeutics. "We believe the use of JSP191 in AVROBIO's Fabry disease and/or Gaucher disease type 1 investigational gene therapy programs offers patients and doctors a compelling new option when it comes to matching a patient's disease with a conditioning agent meeting their therapeutic goals and requirements."

"Jasper is focused on building a leading hematopoietic stem cell therapeutics company with the potential to bring one-time treatments to patients with blood cancers, rare monogenic diseases and autoimmune diseases. Our broad pipeline is led by JSP191, a clinical stage antibody for pre-transplant conditioning, and our engineered hematopoietic stem cells (eHSC), both of which have the potential to be transformative platforms," added Mr. Lis.

Each company will retain commercial rights to their respective technologies.